# Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT00128921** · PHASE2 · TERMINATED · sponsor: **University of Arkansas** · enrollment: 18 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** VELCADE™

## Key facts

- **NCT ID:** NCT00128921
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** study terminated due to low accrual
- **Last updated:** 2012-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128921, "Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00128921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*